DR4 Antibodies

Santa Cruz Biotechnology provides a broad selection of DR4 monoclonal antibodies for advanced research in the field of apoptosis and immune response. DR4 Antibodies are compatible with multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). DR4, also known as death receptor 4, plays a critical role in mediating apoptosis through its interaction with death ligands, such as TRAIL. The receptor is essential for regulating immune responses and has been implicated in cancer biology, making it a significant target for therapeutic interventions. Understanding the function of DR4 is crucial for developing strategies to manipulate cell death pathways in various diseases. DR4 monoclonal antibodies enable researchers to investigate cellular mechanisms and signaling pathways involved in programmed cell death. Studying DR4 expression patterns and interactions provides valuable insights into potential therapeutic approaches for cancer treatment and immune disorders. DR4 monoclonal antibodies ensure reliable results across multiple experimental applications. Santa Cruz Biotechnology monoclonal antibodies for DR4 research support scientists worldwide in advancing our understanding of apoptosis and its role in human health.